Plain-English translation of NCT06812715 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called for people with chronic lymphocytic leukemia (a blood cancer) who have already received other treatments. Specifically, it focuses on patients who previously took another similar drug called zanubrutinib. The study will track how the cancer cells change over time while people take this medication.
Some patients with this type of blood cancer stop responding well to their first treatment, or need a different option. This study is investigating whether this medication can help those patients and understanding how their cancer evolves when taking the new treatment.
You likely qualify if…
You likely don't qualify if…
You would take one 200 mg tablet of the medication by mouth once daily in 28-day cycles for as long as the treatment is helping and you are tolerating it well. You would have regular clinic visits on Day 1 of each cycle, with blood tests and imaging scans to monitor how the cancer is responding. The study involves about 40 participants total, and you would be followed for up to 3 years or until your disease progresses.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Australia